Drug Trial Radar · NCT01000506
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Last checked: Nov 20, 2026Latest source record: Jan 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
621
Actual
Start
Nov 1, 2009
Primary completion
Mar 23, 2012
Study completion Mar 23, 2012
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.
Conditions
- Asthma
Interventions
Mepolizumab 750Biological
Mepolizumab 750mg every four weeks by i.v.
Mepolizumab 250Biological
Mepolizumab 250mg every four weeks by i.v.
Mepolizumab 75Biological
Mepolizumab 75mg every four weeks by i.v.
Placebo salineDrug
Placebo saline every four weeks by i.v.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Clinically Significant Exacerbations of Asthma Per YearTime frame: From randomization (Week 0) to Week 52 or early withdrawal (EW)
Locations
94 sites in 13 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
New Haven, Connecticut
GSK Investigational Site
Albany, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Winston-Salem, North Carolina
GSK Investigational Site
Canton, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Hershey, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Charleston, South Carolina
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Boerne, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Mendoza, Argentina
GSK Investigational Site
San Miguel de Tucumán, Argentina
GSK Investigational Site
Mar del Plata, Buenos Aires, Argentina
GSK Investigational Site
New Lambton, New South Wales, Australia
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Clayton, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Mississauga, Ontario, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Santiago, Chile
GSK Investigational Site
Talcahuano, Chile
GSK Investigational Site
Puente Alto - Santiago, Región Metro de Santiago, Chile
GSK Investigational Site
Valparaíso, Valparaiso, Chile
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.